- Conditions
- HIV-Associated Malignant Neoplasm, HIV Infections, Cancer, AIDS Related Lymphoma, AIDS-related Kaposi Sarcoma, AIDS-Related Malignancy, Anal Cancer, HPV-Related Malignancy
- Interventions
- Non-Interventional, Non-Interventional Follow-up
- Other
- Lead sponsor
- AIDS Malignancy Consortium
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 460 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 15
- States / cities
- La Jolla, California • Washington D.C., District of Columbia • Miami, Florida + 11 more
Location Directory
Clinical trials in Baltimore, Maryland
This page shows live ClinicalTrials.gov search results for Baltimore, Maryland, with direct links to official study records plus on-page filtering and sorting for broad location searches.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official matching trials
13749
Shown on this page
12
Current sort
Recently updated
Location scope
Baltimore, MD
Filters apply within this location only.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Showing 457–468 of 13,749 matching trials in Baltimore, MD.
Live ClinicalTrials.gov results.
Institutions in Baltimore
Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.
Live official records
Open in full search- Conditions
- Metabolic Dysfunction-Associated Steatohepatitis, Non-alcoholic Fatty Liver Disease
- Interventions
- Efimosfermin, Placebo
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 29
- States / cities
- Chandler, Arizona • Mesa, Arizona • Tucson, Arizona + 22 more
- Conditions
- Obesity, Overweight and/or Obesity, Overweight
- Interventions
- PF-08653944, Placebo
- Drug · Other
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 954 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 35
- States / cities
- Canoga Park, California • Escondido, California • Modesto, California + 26 more
- Conditions
- Hypertension, Type 2 Diabetes Mellitus (T2DM)
- Interventions
- Coach-Directed Tailored DASH Groceries Plus Lifestyle Intervention, Self-Shopping DASH diet advice
- Behavioral
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Amyotrophic Lateral Sclerosis
- Interventions
- Not listed
- Lead sponsor
- St. Joseph's Hospital and Medical Center, Phoenix
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 2,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2029
- U.S. locations
- 36
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Irvine, California + 31 more
- Conditions
- Opioid Use Disorder
- Interventions
- Not listed
- Lead sponsor
- Indivior Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 480 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 35
- States / cities
- Costa Mesa, California • Escondido, California • Westport, Connecticut + 31 more
- Conditions
- Next Generation Sequencing (NGS), Surgical Site Infection (SSI), Fracture Fixation
- Interventions
- NGS diagnostic findings
- Diagnostic Test
- Lead sponsor
- Johns Hopkins Bloomberg School of Public Health
- Other
- Eligibility
- 18 Years to 84 Years
- Enrollment
- 250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2028
- U.S. locations
- 18
- States / cities
- Tuscaloosa, Alabama • Los Angeles, California • San Francisco, California + 15 more
- Conditions
- Mental Disorders, Severe
- Interventions
- Medherent
- Other
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 18 Years to 88 Years
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2028
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Opioid Use Disorder, Chronic Pain
- Interventions
- Patient-Oriented Dosing (POD), Pain Self-Management (PSM), Usual Care, Standard Buprenorphine Dosing Condition
- Drug · Behavioral
- Lead sponsor
- Erin Winstanley
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 273 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 13
- States / cities
- Baltimore, Maryland • Dundalk, Maryland • Hagerstown, Maryland + 6 more
- Conditions
- Respiratory Syncytial Virus (RSV)
- Interventions
- Arexvy (2 doses total), Arexvy (3 doses total), Arexvy (1 dose total), Placebo
- Biological · Other
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 170 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Progressive Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis (IPF)
- Interventions
- AP01
- Combination Product
- Lead sponsor
- Avalyn Pharma Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 340 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 32
- States / cities
- Birmingham, Alabama • Los Angeles, California • Newport Beach, California + 24 more
- Conditions
- Mature B-Cell Non-Hodgkin Lymphoma
- Interventions
- Obinutuzumab, Glofitamab, Rituximab, Ifosfamide, Carboplatin, Etoposide, Tocilizumab
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 6 Months to 30 Years
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2032
- U.S. locations
- 10
- States / cities
- Birmingham, Alabama • Oakland, California • Roseville, California + 6 more